Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Australian Cancer Technology expands pipeline with European and U.S. focus

Jan. 16, 2004

Chiron expands its phase II program for IL-2 in the treatment of lymphoma

Jan. 15, 2004

Favrille completes enrollment in a phase II clinical trial of FavId for fNHL

Jan. 13, 2004

ImmunoGen to advance TAP compounds into proof-of-concept trials

Jan. 12, 2004

Aphton commences Australian regulatory filing for G17DT

Jan. 8, 2004

Kyowa Hakko presents anti-hIGF antibodies and their therapeutic use

Jan. 8, 2004

DMC recommends continuation of phase III Oncophage trial

Jan. 5, 2004

Sixteenth Medarex fully human antibody enters clinical development

Dec. 30, 2003

Genmab files to conduct phase I/II HuMax-CD20 trial for NHL

Dec. 29, 2003

Phase II Pentrix trial cleared to commence

Dec. 23, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...